Drug intelligence / Profile preview

alpibectir + ethionamide + rifampicin + ethambutol + pyrazinamide

Development stage
Unknown
Lead developer
BioVersys
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination therapy for tuberculosis that includes alpibectir, a novel small molecule that significantly potentiates the activity of ethionamide by acting on transcriptional regulators of Mycobacterium tuberculosis (Mtb), along with standard first-line TB drugs (rifampicin, ethambutol, and pyrazinamide). Alpibectir stimulates novel bioactivation pathways for ethionamide, increasing its efficacy while simultaneously overcoming ethionamide resistance. The combination is being developed for pulmonary and meningeal tuberculosis.

02

Targets

rpoB (DNA-directed RNA polymerase subunit beta)EthR;EthR2 (EthR/EthR2)VirS (VirS sensor histidine kinase)InhAMultiple pyrazinamide-associated bacterial targets/processesAftA (Arabinosyltransferase AftA)

Beyond the preview

Go deeper on alpibectir + ethionamide + rifampicin + ethambutol + pyrazinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpibectir + ethionamide + rifampicin + ethambutol + pyrazinamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call